Navepegritide + Placebo for navepegritide
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Dec 10, 2024 → Jan 1, 2027
NCT ID
NCT06732895About Navepegritide + Placebo for navepegritide
Navepegritide + Placebo for navepegritide is a phase 2 stage product being developed by Ascendis Pharma for Achondroplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06732895. Target conditions include Achondroplasia.
What happened to similar drugs?
0 of 3 similar drugs in Achondroplasia were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06732895 | Phase 2 | Recruiting |
| NCT06079398 | Phase 2 | Recruiting |
Competing Products
20 competing products in Achondroplasia